Form 4: Sutro Biopharma Director Granted Stock Options

Sutro Biopharma Director Connie Matsui received a grant of 1,500 stock options with a $10.38 exercise price, vesting monthly over six months.

Summary

• Connie Matsui, a Director of Sutro Biopharma, Inc. (STRO), was granted 1,500 stock options.
• The options have an exercise price of $10.38 per share.
• The grant date for these options was December 23, 2025.
• The options will vest at a rate of 16.67% of the total award monthly, contingent on Ms. Matsui's continued service to the company.
• The first vesting tranche is scheduled for January 23, 2026.
• The options have an expiration date of December 23, 2035.
• Following this transaction, Ms. Matsui beneficially owns 1,500 derivative securities.
• A Limited Power of Attorney, dated October 6, 2025, authorizes Regina Cheng, David Pauling, and Gregory Chow to execute SEC filings on behalf of Connie Matsui.

Sentiment

Score: 6

Explanation: A neutral to slightly positive event. It's a routine compensation action that aligns director interests with shareholders, but doesn't indicate significant operational news or financial performance.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's performance or strategy. It solely reports an insider transaction.

Industry Context

This is a routine insider transaction (option grant) for a director. Such grants are common practice in the biopharma industry to attract and retain talent and align interests, especially for directors who provide strategic oversight. It does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in the biopharmaceutical industry and broader corporate governance to incentivize long-term commitment and align interests with shareholders.
• The vesting schedule (monthly over approximately 6 months for 16.67% monthly) is a common mechanism to ensure continued service, similar to practices seen in companies like Amgen or Gilead Sciences for their non-employee directors, though specific terms vary.
• The exercise price being set at the market price on the grant date is typical for incentive stock options, ensuring the director benefits only if the stock appreciates.

Corporate Governance

Related Party Transactions

• The stock option grant to a director is a related party transaction, which is a standard compensation practice disclosed transparently.

Stakeholder Impact

• Shareholders: The option grant aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value.
• Management: The Power of Attorney streamlines compliance for the director and the company's legal/compliance team.

Next Steps

• Continued service by Connie Matsui to ensure vesting of the stock options.
• Future SEC Form 4 filings will be required for any subsequent transactions by Connie Matsui.

Key Dates

Recommendation

This Form 4 filing reports a routine stock option grant to a director, which is a standard compensation practice. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Sutro Biopharma, STRO, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Connie Matsui, Biopharma